Research dossier
Clinical research on Rhodiola rosea
8 trials reviewed across 5 indications.
Strongest evidence
Fatigue & burnout under stress
Mechanism
Salidroside and rosavins appear to modulate the HPA stress axis (Olsson 2009 saw a blunted cortisol awakening response) and influence monoamine and AMPK/heat-shock-protein signaling. The effect is best described as anti-fatigue under stress load rather than stimulant energy.
This is rhodiola's strongest claim. Multiple small RCTs (students, night-shift physicians, burnout patients) show reduced mental fatigue and improved concentration at 100–576 mg/day of SHR-5 over 2–4 weeks. Effects are real but modest, short-term, and concentrated in stressed populations.
Benefit is clearest in people under acute or chronic stress load (exams, shift work, burnout). Don't expect a noticeable lift if you're rested and unstressed.
Trials cited
Spasov — SHR-5 for exam-stress fatigue in students
positive · RCT
Spasov et al., 2000, Phytomedicinen=40Industry-funded40 students on 100 mg/day SHR-5 during exams improved on mental fatigue, physical fitness, and neuro-motor tests (p<0.01) and rated their general well-being higher than placebo (p<0.05). Notably, a text-proofreading task and a simple finger-tapping speed test did NOT differ from placebo — the effect was real but not across-the-board.
Small (n=40), short (20 days), single-extract, and authored by researchers tied to the SHR-5 maker (Swedish Herbal Institute). Selective endpoint improvement.
Darbinyan — SHR-5 for physician night-duty fatigue
positive · RCT
Darbinyan et al., 2000, Phytomedicinen=56Industry-funded56 physicians on a 2-week course of low-dose SHR-5 during night duty improved on a composite mental-fatigue index versus placebo in the first treatment period. The effect on the fatigue index was statistically significant; this is the most-cited rhodiola fatigue trial.
Crossover with a short 2-week period and no washout reported between some phases. Single proprietary extract; ties to the SHR-5 manufacturer. Benefit waned after the first period.
Olsson — SHR-5 for stress-related fatigue (burnout)
positive · RCT
Olsson, von Schéele, Panossian, 2009, Planta Medican=60Industry-funded60 burnout patients on 576 mg/day SHR-5 for 28 days showed greater improvement on the Pines Burnout scale and concentration tests than placebo, plus a blunted cortisol awakening response — a plausible HPA-axis mechanism. The best-designed of the rhodiola fatigue trials.
Still small (n=60) and short (4 weeks). Conducted with the SHR-5 extract maker's involvement. No long-term follow-up.
Edwards — WS 1375 for life-stress symptoms (open-label)
positive · Pilot
Edwards, Heufelder, Zimmermann, 2012, Phytotherapy Researchn=101Industry-funded101 stressed adults on 400 mg/day WS 1375 for 4 weeks reported clinically relevant improvements in stress symptoms, fatigue, and disability, with most gains appearing in the first week. Consistent with the SHR-5 fatigue signal.
Open-label, single-arm, NO placebo control and NO randomization — the entire effect could be expectancy and natural symptom fluctuation. Useful as supportive context only, not as efficacy proof. Manufacturer (Dr. Willmar Schwabe) extract.
Hung — systematic review of rhodiola RCTs
mixed · Systematic review
Hung, Perry, Ernst, 2011, Phytomedicinen=11Pooled 11 placebo-controlled RCTs. Concluded rhodiola 'may have beneficial effects on physical performance, mental performance, and certain mental health conditions,' but flagged the decisive weakness: almost no independent replication — most positive trials trace back to the same research group and the same proprietary extract.
Methodological quality was rated moderate-to-good, but the lack of independent replication and contradictory results mean the authors stopped well short of endorsing efficacy. The honest summary of the entire literature.
Stress symptoms & subjective well-being
Mechanism
Proposed HPA-axis modulation — dampening the cortisol response to acute stress. The mechanistic story overlaps with the fatigue benefit; they are likely the same effect measured on different scales.
Stressed adults report improved well-being and lower stress-symptom scores on SHR-5/WS 1375. But the strongest 'stress' data (Edwards 2012) is open-label with no placebo, and the placebo-controlled signal is small. Treat as supportive, not established.
The headline open-label trial had no control group, so expectancy effects can't be ruled out. Effect sizes in the controlled trials are modest.
Olsson — SHR-5 for stress-related fatigue (burnout)
positive · RCT
Olsson, von Schéele, Panossian, 2009, Planta Medican=60Industry-funded60 burnout patients on 576 mg/day SHR-5 for 28 days showed greater improvement on the Pines Burnout scale and concentration tests than placebo, plus a blunted cortisol awakening response — a plausible HPA-axis mechanism. The best-designed of the rhodiola fatigue trials.
Still small (n=60) and short (4 weeks). Conducted with the SHR-5 extract maker's involvement. No long-term follow-up.
Edwards — WS 1375 for life-stress symptoms (open-label)
positive · Pilot
Edwards, Heufelder, Zimmermann, 2012, Phytotherapy Researchn=101Industry-funded101 stressed adults on 400 mg/day WS 1375 for 4 weeks reported clinically relevant improvements in stress symptoms, fatigue, and disability, with most gains appearing in the first week. Consistent with the SHR-5 fatigue signal.
Open-label, single-arm, NO placebo control and NO randomization — the entire effect could be expectancy and natural symptom fluctuation. Useful as supportive context only, not as efficacy proof. Manufacturer (Dr. Willmar Schwabe) extract.
Spasov — SHR-5 for exam-stress fatigue in students
positive · RCT
Spasov et al., 2000, Phytomedicinen=40Industry-funded40 students on 100 mg/day SHR-5 during exams improved on mental fatigue, physical fitness, and neuro-motor tests (p<0.01) and rated their general well-being higher than placebo (p<0.05). Notably, a text-proofreading task and a simple finger-tapping speed test did NOT differ from placebo — the effect was real but not across-the-board.
Small (n=40), short (20 days), single-extract, and authored by researchers tied to the SHR-5 maker (Swedish Herbal Institute). Selective endpoint improvement.
Mood & depression
Mechanism
Hypothesized monoaminergic effects (MAO inhibition, serotonin/dopamine modulation) from salidroside, extrapolated largely from preclinical models.
One small RCT (Darbinyan 2007) found rhodiola beat placebo for mild-to-moderate depression. But the cleaner, US-academic trial (Mao 2015) found neither rhodiola nor sertraline separated from placebo. The depression evidence is genuinely weak and contradictory — don't use rhodiola as a standalone antidepressant.
Contradictory trials. Not a substitute for evidence-based depression treatment; discuss with a clinician before relying on it for mood.
Darbinyan — SHR-5 for mild-to-moderate depression
positive · RCT
Darbinyan et al., 2007, Nordic Journal of Psychiatryn=8989 patients across 340 mg/day, 680 mg/day, and placebo arms. Both rhodiola groups improved on overall depression, insomnia, emotional instability, and somatization versus placebo over 6 weeks; self-esteem did not improve. The only randomized rhodiola depression trial showing a clear placebo separation.
Single small site, short duration, and never independently replicated. The one larger and more rigorous depression trial (Mao 2015) failed to separate from placebo — see notable null results.
Mao — Rhodiola vs sertraline for major depression
Null · RCT
Mao et al., 2015, Phytomedicinen=57Three-arm trial at the University of Pennsylvania. Neither rhodiola NOR sertraline beat placebo on HAM-D (p=0.79 across groups). Reductions were 'modest, albeit statistically non-significant' in all arms. Rhodiola had fewer side effects than sertraline, but the headline 'as effective as an antidepressant' framing rests on a trial where nothing separated from placebo.
Underpowered to detect small effects by the authors' own admission — but the cleaner, US-academic design failed to reproduce Darbinyan 2007. This is the most important honest counterweight to the depression claim.
Athletic & physical performance
Mechanism
Proposed reductions in perceived exertion and oxidative stress during exercise; mechanistically plausible but not consistently demonstrated.
A single acute dose modestly raised endurance and VO2max in De Bock 2004 — but 4 weeks of daily use added nothing, and strength and reaction time were unchanged. Across the broader literature the performance results are contradictory. This is a weak, inconsistent claim.
Any benefit appears acute (taken before a session), not from chronic loading. Inconsistent across trials — do not count on it for training adaptation.
De Bock — acute vs chronic rhodiola for exercise capacity
mixed · RCT
De Bock et al., 2004, International Journal of Sport Nutrition and Exercise Metabolismn=24A single acute 200 mg dose modestly improved endurance capacity and VO2max (roughly 3–6%). But 4 weeks of daily dosing added NOTHING beyond the acute effect, and strength, reaction time, and attention were unchanged. The athletic-performance story is small, acute-only, and inconsistent.
Very small (n=24). The acute-but-not-chronic pattern is the opposite of how an adaptogen is marketed (as a build-up tonic), and later sport trials have been contradictory.
Hung — systematic review of rhodiola RCTs
mixed · Systematic review
Hung, Perry, Ernst, 2011, Phytomedicinen=11Pooled 11 placebo-controlled RCTs. Concluded rhodiola 'may have beneficial effects on physical performance, mental performance, and certain mental health conditions,' but flagged the decisive weakness: almost no independent replication — most positive trials trace back to the same research group and the same proprietary extract.
Methodological quality was rated moderate-to-good, but the lack of independent replication and contradictory results mean the authors stopped well short of endorsing efficacy. The honest summary of the entire literature.
Cognition & mental performance
Mechanism
Likely secondary to the anti-fatigue effect — when fatigue drops, concentration and processing speed measures improve. Not evidence of a direct nootropic action.
Concentration and mental-fatigue measures improve in stressed, fatigued people (students at exam time, physicians on nights). But effects are selective — some cognitive tasks improved while others (proofreading, finger-tapping) did not — and the gains likely ride on reduced fatigue rather than enhanced cognition per se.
Improvements show up mainly in fatigued or sleep-deprived states. No good evidence rhodiola enhances cognition in well-rested healthy adults.
Spasov — SHR-5 for exam-stress fatigue in students
positive · RCT
Spasov et al., 2000, Phytomedicinen=40Industry-funded40 students on 100 mg/day SHR-5 during exams improved on mental fatigue, physical fitness, and neuro-motor tests (p<0.01) and rated their general well-being higher than placebo (p<0.05). Notably, a text-proofreading task and a simple finger-tapping speed test did NOT differ from placebo — the effect was real but not across-the-board.
Small (n=40), short (20 days), single-extract, and authored by researchers tied to the SHR-5 maker (Swedish Herbal Institute). Selective endpoint improvement.
Darbinyan — SHR-5 for physician night-duty fatigue
positive · RCT
Darbinyan et al., 2000, Phytomedicinen=56Industry-funded56 physicians on a 2-week course of low-dose SHR-5 during night duty improved on a composite mental-fatigue index versus placebo in the first treatment period. The effect on the fatigue index was statistically significant; this is the most-cited rhodiola fatigue trial.
Crossover with a short 2-week period and no washout reported between some phases. Single proprietary extract; ties to the SHR-5 manufacturer. Benefit waned after the first period.
Hung — systematic review of rhodiola RCTs
mixed · Systematic review
Hung, Perry, Ernst, 2011, Phytomedicinen=11Pooled 11 placebo-controlled RCTs. Concluded rhodiola 'may have beneficial effects on physical performance, mental performance, and certain mental health conditions,' but flagged the decisive weakness: almost no independent replication — most positive trials trace back to the same research group and the same proprietary extract.
Methodological quality was rated moderate-to-good, but the lack of independent replication and contradictory results mean the authors stopped well short of endorsing efficacy. The honest summary of the entire literature.
3 forms of Rhodiola rosea compared
SHR-5 (Swedish Herbal Institute)
SHR-5 standardized extract
Standardized to ~3% rosavins / ~0.8–1% salidroside
Best forFatigue, burnout, stress — the extract behind nearly every positive rhodiola trialAlmost the entire positive evidence base (Spasov, Darbinyan, Olsson, Mao) used SHR-5 or the near-identical WS 1375. Trial doses ranged 100–576 mg/day. If a product doesn't name SHR-5/WS 1375 or state the rosavin/salidroside percentages, you cannot assume it behaves like the studied material.
energy100–576 mgstress200–576 mgStandardized Rhodiola rosea extract (3% rosavins / 1% salidroside)
Variable — quality depends entirely on verified standardization
Best forGeneral adaptogenic / anti-fatigue useThe clinically meaningful standard is 3% rosavins to 1% salidroside (roughly the natural ~3:1 ratio in R. rosea root). A genuine 3% rosavin / 1% salidroside extract at 200–600 mg/day is the closest match to the trial material when a branded SHR-5 product isn't available.
energy144–400 mgGeneric / unstandardized Rhodiola
Unknown — frequently adulterated or under-dosed
Best forBlack box — avoid if standardization is not statedRhodiola rosea is one of the most commonly adulterated botanicals: cheaper Rhodiola species (R. crenulata, R. kirilowii) and synthetic salidroside or rosavin are routinely substituted. A label that only says 'Rhodiola' with no species, no standardization, and no rosavin/salidroside percentage is a genuine unknown.
Are you deficient? Symptoms, risk groups, lab tests
Rhodiola is an adaptogenic botanical, not a nutrient — there is no dietary requirement and no 'rhodiola deficiency.' It is supplemented for the pharmacological effect of its rosavins and salidroside, primarily on stress-related fatigue.
Side effects and drug interactions
Side effects
Overstimulation / jitteriness
Uncommon · More common above ~400–600 mg/day or with evening dosing
Rhodiola can feel mildly stimulating — some users report restlessness, irritability, or a 'wired' feeling, especially at higher doses or taken late in the day.
Insomnia
Uncommon
Because of its activating quality, rhodiola taken in the afternoon or evening can interfere with sleep onset. Best dosed in the morning.
Dizziness or dry mouth
Uncommon
Mild and transient; reported in a minority of trial participants.
Headache or GI upset
Common
Occasional, usually mild. Generally well tolerated across the trials, which reported only minor adverse events.
Drug interactions
Additive effect
stimulants (caffeine, ADHD medications)MAO inhibitors (theoretical)Rhodiola is mildly activating and has shown MAO-inhibitory activity in vitro. Stacking with stimulants could compound overstimulation; the MAOI concern is theoretical but worth flagging.
Avoid combining with other strong stimulants if you're prone to jitteriness. If you take an MAOI, discuss with your prescriber.
Other
antidepressants (SSRIs, SNRIs)antihypertensivesantidiabetic medications (theoretical)Theoretical pharmacodynamic overlap — possible additive serotonergic, blood-pressure, or glucose effects. Clinical interaction data in humans is essentially absent.
No well-documented interactions, but tell your clinician if you take psychiatric or cardiovascular medication before adding rhodiola.
Other
CYP-metabolized and P-glycoprotein substrate drugs (theoretical)In-vitro signals suggest rhodiola may affect some CYP enzymes and drug transporters; the clinical relevance is unestablished.
If you take a narrow-therapeutic-index drug, mention rhodiola to your prescriber. Theoretical, not demonstrated, risk.
Other critical caveats
- Standardization is the whole game — and rhodiola is heavily adulterated. Buy extract verified to ~3% rosavins / 1% salidroside (ideally SHR-5 / WS 1375). Cheaper Rhodiola species and synthetic salidroside/rosavin are routinely substituted, so a generic 'Rhodiola 500mg' is a genuine unknown.
- Nearly every positive trial used one proprietary extract (SHR-5/WS 1375) from a small cluster of researchers, and a 2011 systematic review flagged the lack of independent replication as the central weakness. Take the fatigue signal as promising-but-unproven.
- The depression evidence is contradictory: one small positive trial (Darbinyan 2007) versus a cleaner US trial (Mao 2015) where neither rhodiola nor an actual antidepressant beat placebo. Do not use rhodiola as a standalone antidepressant.
- Rhodiola is mildly activating — dose it in the morning. Afternoon or evening dosing can cause insomnia or a jittery, overstimulated feeling.
- Safety data beyond ~12 weeks is essentially absent, and there is no pregnancy safety data. Avoid in pregnancy and breastfeeding.
Frequently asked
Does rhodiola actually work?
For stress-related fatigue and burnout, the evidence is modest but real: small RCTs in students, night-shift physicians, and burnout patients show reduced mental fatigue and improved concentration on 100–576 mg/day of the standardized SHR-5 extract. The big asterisk is that almost every positive trial used the same proprietary extract from the same research cluster, with little independent replication. For mood, athletic performance, and cognition in healthy people, the evidence is weak or contradictory.What should I look for on the label?
Standardization to 3% rosavins and 1% salidroside — that's the ratio matched to the studied extracts. Branded SHR-5 or WS 1375 is the gold standard. Rhodiola is one of the most adulterated botanicals sold (cheaper species and synthetic actives get substituted), so a product that only says 'Rhodiola 500mg' with no species and no rosavin/salidroside percentage isn't trustworthy.How much rhodiola should I take, and when?
Trials used 100–576 mg/day of standardized SHR-5; a common practical range is 200–400 mg/day of a 3% rosavin / 1% salidroside extract. Take it in the morning — rhodiola is mildly stimulating, and afternoon or evening dosing can keep you awake. Effects on fatigue can appear within the first week or two.Will rhodiola help my depression or anxiety?
The honest answer is the evidence is weak. One small trial found a benefit for mild-to-moderate depression, but a more rigorous trial found neither rhodiola nor the antidepressant sertraline beat placebo. It is not a substitute for evidence-based treatment. If you're managing depression or significant anxiety, talk to a clinician rather than relying on rhodiola.Is rhodiola safe?
It's generally well tolerated in the short trials, with only mild side effects — occasional overstimulation, jitteriness, dry mouth, or sleep disruption if taken late. There's no good safety data beyond about 12 weeks and none in pregnancy, so avoid it if pregnant or breastfeeding, and flag it to your prescriber if you take stimulants or psychiatric medication.
References
- 01Examine.com — Rhodiola rosea
- 02NCCIH — Rhodiola
- 03Hung, Perry, Ernst 2011 — Systematic review of Rhodiola rosea RCTs (Phytomedicine)
- 04Olsson et al. 2009 — SHR-5 for stress-related fatigue (Planta Medica)
- 05Mao et al. 2015 — Rhodiola vs sertraline for major depression (Phytomedicine)
Last reviewed2026-05-24